3 FEBRUARY 2005

NEW ZEALAND GAZETTE, No. 32

Cinchocaine; for external use in medicines containing 0.5%
or less

Datura spp; for oral use in liquid form in medicines
containing 0.03% or less and 0.3 milligrams or less per
dose and not more than 1.2 milligrams per recommended
daily dose of total solanaceous alkaloids or in solid dose
form in medicines containing 0.3 milligrams or less
per dose form and not more than 1.2 milligrams per
recommended daily dose of total solanaceous alkaloids

Dextromethorphan; in liquid form containing more than
0.25% or in solid dose form containing more than 15
milligrams per dose form when in packs containing not
more than 600 milligrams and with a recommended daily
dose of not more than 120 milligrams

Diclofenac; in solid dose form containing 12.5 milligrams or
less per dose form in packs of not more than 20 tablets
or capsules

Duboisia leichhardtii; for oral use in liquid form in
medicines containing 0.03% or less and 0.3 milligrams
or less per dose and not more than 1.2 milligrams per
recommended daily dose of total solanaceous alkaloids
or in solid dose form in medicines containing 0.3
milligrams or less per dose form and not more than
1.2 milligrams per recommended daily dose of total
solanaceous alkaloids

Duboisia myoporides; for oral use in liquid form in
medicines containing 0.03% or less and 0.3 milligrams
or less per dose and not more than 1.2 milligrams per
recommended daily dose of total solanaceous alkaloids
or in solid dose form in medicines containing 0.3
milligrams or less per dose form and not more than
1.2 milligrams per recommended daily dose of total
solanaceous alkaloids

Fluorides; for internal use in medicines containing 2.2
milligrams or less per dose form of sodium fluoride; for
external use in medicines other than pastes, gels or
powders for cleaning the teeth containing 2.5% or less;
except in oral hygiene products other than pastes, gels or
powders for cleaning the teeth containing 0.01% or less

Flurbiprofen; in throat lozenges containing 10 milligrams or
less per lozenge

*Fluticasone; in aqueous nasal sprays delivering up to
50 micrograms per actuation when the maximum
recommended daily dose is not greater than 200
micrograms and the medicine has received the consent of
the Minister or the Director-General to its distribution as
a pharmacy-only medicine

Folic acid; for oral use in medicines containing more than
500 micrograms per recommended daily dose

Folinic acid; for oral use in medicines containing more than
500 micrograms per recommended daily dose

Glyceryl trinitrate; for external use; except in medicines
containing 100 micrograms or less per litre or per
kilogram

Hydroquinone; for external use in medicines containing 2%
or less except in hair preparations containing 1% or less

Hyoscine; for transdermal use in medicines containing
2 milligrams or less of total solanaceous alkaloids per
dose unit; for oral use in liquid form in medicines
containing 0.03% and 0.3 milligrams or less per dose
and not more than 1.2 milligrams per recommended
daily dose or in solid dose form in medicines containing
0.3 milligrams or less per dose unit and not more than 1.2
milligrams per recommended daily dose of total
solanaceous alkaloids

Hyoscyamine; for external use in medicines containing
0.03% or less of total solanaceous alkaloids; for oral use
in liquid form in medicines containing 0.03% and

769

0.3 milligrams or less per dose and not more than 1.2
milligrams per recommended daily dose or in solid dose
form in medicines containing 0.3 milligrams or less
per dose unit and not more than 1.2 milligrams per
recommended daily dose of total solanaceous alkaloids

Hyoscyamus niger; for oral use in liquid form in medicines
containing 0.03% and 0.3 milligrams or less per dose
and not more than 1.2 milligrams per recommended
daily dose of total solanaceous alkaloids or in solid dose
form in medicines containing 0.3 milligrams or less
per dose unit and not more than 1.2 milligrams per
recommended daily dose except in packs containing
30 micrograms or less of total solanaceous alkaloids

*Ibuprofen; for oral use in liquid form in packs containing
not more than 4 grams in medicines which have received
the consent of the Minister or the Director-General to
their sale as pharmacy-only medicines and which are
sold in the manufacturer’s original pack; for oral use in
solid dose form containing not more than 200 milligrams
per dose form in medicines which have received the
consent of the Minister or the Director-General to their
sale as pharmacy-only medicines and which are sold
in the manufacturer’s original pack; except in packs
containing 200 milligrams or less per oral solid dose
form and not more than 25 dose units per pack when
in medicines which have received the consent of the
Minister or the Director-General to their sale as general
sale medicines and which are sold in the manufacturer’s
original pack

Lignocaine; for external use in medicines containing 10% or
less and more than 2%; for urethral use

Minoxidil; for external use in medicines containing 5% or
less

*Mometasone; in aqueous nasal sprays delivering up to
50 micrograms per actuation when the maximum
recommended daily dose is not greater than 200
micrograms and the medicine has received the consent of
the Minister or the Director-General to its distribution as
a pharmacy-only medicine

Nicotine; for inhalation or in lozenges or sublingual tablets
except when sold from a smoking cessation clinic run
under the auspices of a registered medical practitioner,
nurse, pharmacist or psychologist

*Nizatidine; in medicines which have received the consent
of the Minister or the Director-General to their sale as
pharmacy-only medicines and which are sold in the
manufacturer’s original pack containing not more than
14 days’ supply

Nystatin; for dermal use

Podophyllum emodi; for external use for the treatment
of warts other than anogenital warts in medicines
containing 10% or less of podophyllin

Podophyllum peltatum; for external use for the treatment
of warts other than anogenital warts in medicines
containing 10% or less of podophyllin

Podophyllotoxin; for external use for the treatment of
warts other than anogenital warts in medicines
containing 0.5% or less

Potassium chlorate; except in medicines containing 10%
or less

Prilocaine; for dermal use in medicines containing 10%
or less

Pyrithione zinc; for external use in medicines containing
more than 2%

Sabadilla; in packs containing 18 milligrams or less of total
alkaloids except in packs containing 1.8 milligrams
or less and a recommended daily dose of not more than
0.6 milligrams of total alkaloids